Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06087029 · ClinicalTrials.gov registry record · NA
IMPRoving Outcomes in Vascular DisEase - Aortic Dissection
A NA study of Type B Aortic Dissection, sponsored by Duke University.
- Recruiting
- Registry status
- NA
- Development phase
- 1,100
- Enrollment target
- 20
- Study locations
NCT06087029: Recruiting NA study of Type B Aortic Dissection, sponsored by Duke University.
NCT06087029 is a NA study of Type B Aortic Dissection that is actively recruiting participants, run by Duke University. The registered enrollment target is 1,100 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (22% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06087029, a NA study of Type B Aortic Dissection, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to determine whether an upfront invasive strategy of TEVAR plus medical therapy reduces the occurrence of a composite endpoint of all-cause death or major aortic complications compared to an upfront conservative strategy of medical therapy with surveillance for deterioration in patients with uncomplicated type B aortic dissection.
Primary Outcome
The primary endpoint is a composite of all-cause death or major aortic complications (MAC). MACs are defined as: * Aortic rupture * Malperfusion syndrome * New aortic tear requiring intervention, * Retrograde aortic dissection, * Dependence on outpatient dialysis (chronic) * Major amputation (above ankle) * Tracheostomy * fistula formation (e.g., aorto-esophageal, aorto-tracheal) * Spinal Cord Ischemia with paralysis or paresis * Stroke * AD-related intervention in either group defined as: *
Conditions Studied
Interventions
- PROCEDURE TEVAR
- OTHER Guideline directed medical therapy and surveillance of dissection
Study Locations (20)
California
- Memorial Care Long Beach Medical Center - Long Beach
- Keck Medical Center of USC - Los Angeles
- University of California San Diego - San Diego
- University of California - San Francisco
- Stanford University Medical Center - Stanford
Illinois
- Northwestern University - Chicago
- The University of Chicago - Chicago
- Southern Illinois University School of Medicine - Springfield
Colorado
- University of Colorado Denver - Aurora
- Memorial Hospital Central - Colorado Springs
Connecticut
- Hartford Hospital - Hartford
- Yale University - New Haven
Florida
- University of Florida Health - Gainesville
- Tampa General Hospital - Tampa
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Honorhealth - Phoenix
Indiana
- Indiana University Methodist Hospital - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,100 participants |
| Start Date | 2024-04-14 |
| Est. Completion | 2030-06-30 |
| Phase | NA |
What NCT06087029 shows while recruiting
NCT06087029 is an interventional study that assigns participants to a tested intervention. Its 1,100 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (22% lower).
The record links to 1 condition, with Type B Aortic Dissection appearing as the primary indexed condition, and to 2 interventions - of which TEVAR is the first listed.
NCT06087029 names 20 study sites across 11 states, led by California, Illinois, Colorado.
Frequently Asked Questions
What is clinical trial NCT06087029 about?
NCT06087029 is a clinical study titled "IMPRoving Outcomes in Vascular DisEase - Aortic Dissection". The goal of this clinical trial is to determine whether an upfront invasive strategy of TEVAR plus medical therapy reduces the occurrence of a composite endpoint of all-cause death or major aortic complications compared to an upfront conservative strategy of medical therapy with surveillance for det...
What is the current status of trial NCT06087029?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,100 participants. The study started on 2024-04-14. Estimated completion is 2030-06-30.
What conditions does trial NCT06087029 study?
This clinical trial studies the following conditions: Type B Aortic Dissection.
What interventions are being tested in trial NCT06087029?
The interventions under investigation include: TEVAR (PROCEDURE), Guideline directed medical therapy and surveillance of dissection (OTHER).
Who is sponsoring clinical trial NCT06087029?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06087029 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06087029's enrollment target sits among peer trials
1,100 93rd of 2000 higher than 1,907 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00710112 · 1,100 participants
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants
- NCT02688517 · 1,100 participants
Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
- NCT04743765 · 1,100 participants · NA
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
- NCT05638581 · 1,100 participants · Phase 3
Trauma Resuscitation With Low-Titer Group O Whole Blood or Products
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI